NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Plexus Ventures, LLC
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Plexus Ventures Announces Assignment from U.S Pharmacia Participation in BIO 2008 - Plexus Ventures announces a new assignment from US Pharmacia and Participation in the BIO 2008 International Conference
Plexus Ventures Announces Assignment from U.S Pharmacia Participation in BIO 2008

 

NewswireToday - /newswire/ - London, United Kingdom, 2008/05/21 - Plexus Ventures announces a new assignment from US Pharmacia and Participation in the BIO 2008 International Conference.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Plexus Ventures is pleased to announce its appointment by US Pharmacia (Warsaw, Poland) to augment the company's internal resources by providing additional business development services.

Michael O'Sullivan, Managing Director of Plexus Ventures, commented: "With 12 seasoned business development professionals in nine cities worldwide, Plexus Ventures is well-positioned to help US Pharmacia, Poland's leading OTC company, to achieve its growth objectives."

About US Pharmacia

US Pharmacia is the leading OTC company in the Polish market and ranks as the 5th largest OTC company in Europe. US Pharmacia markets well-known consumer brands in the analgesic, cough/cold, GI, allergy and vitamin categories.

Plexus Ventures Chairs Japan Business Development Session at BIO 2008

Plexus Ventures, a leading business development consultancy specializing in pharmaceuticals and biotechnology transactions, announced today that Richard A. Brown, General Partner and Head of Tokyo Office will chair a breakout session at the 2008 BIO International Convention. The session is titled "Not Lost in Translation: Successfully Forging Japanese Pharma and Western Biotech Collaborations" and is part of the "Doing Business Globally" track at the conference taking place June 17-20, 2008 in San Diego, CA.

Mr. Brown's workshop includes speakers from both Western and Japanese companies who have entered into such collaborations, who will discuss practical considerations and funding advantages of working with a Japanese partner, the Japanese business model, deal-making strategies and cultural considerations. Through presentations from four speakers, business development executives and others involved in the deal-making process will hear the perspectives of both sides of these East-West collaborations, and how one manages the entire deal process, from relationship-building, negotiating, structuring the deal, and implementing the collaboration.

Confirmed participants for the June 17, 2008 session are: Jeffrey Abbey, Vice President, Business Development, Argos Therapeutics; Pär Gellerfors, Ph.D., Chief Executive Officer, BioArctic Neuroscience AB; Hideki Hayashi, Senior Vice President, Corporate Business Development, Eisai Co., Ltd.; and Tamao Watanabe, Senior Manager of Business Development, Kirin Pharma Company Limited;

Plexus Ventures' Tokyo office assists Japanese companies to establish and grow their presence outside Japan and Western companies who wish to partner their assets with Japanese. Mr. Brown is active in the Japanese business development community, is a member of PharmaDelegates and the Japanese Pharmaceutical Licensing Association, and has been a regular guest lecturer at the Business Development Training Seminars conducted by Yamasaki Pharma Consulting in Tokyo and Osaka.

"Not Lost in Translation: Successfully Forging Japanese Pharma and Western Biotech Collaborations" takes place on Tuesday June 17, 2008 from 8:15 - 9:45 AM as part of the 2008 BIO International Convention at San Diego Convention Center. In addition to Mr. Brown, Mr. Pino Modica, Managing Partner of Plexus Ventures will be in attendance throughout the BIO Convention. To inquire about meeting availability, please e-mail mas[.]plexusventures.com.

About Plexus Ventures

Plexus Ventures (plexusventures.com), founded in 1990, provides strategic advice, business development and alliance management services to clients in the pharmaceutical, biotechnology and drug delivery industries worldwide. Plexus Ventures assists its clients in the areas of in-licensing, out-licensing, acquisitions, divestitures and strategic partnerships. With offices in Frankfurt, Indianapolis, London, Los Angeles, Milan, Philadelphia, Tokyo and Warsaw, Plexus Ventures possesses the capabilities to effectively serve clients in the United States, Europe and Asia. Plexus Ventures is both well-known and well respected by leading research-based pharmaceutical companies worldwide.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Plexus Ventures, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Plexus Ventures Announces Assignment from U.S Pharmacia Participation in BIO 2008

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Mary Alice Strong - PlexusVentures.com 
310-315-7106 maryalice_strong[.]plexusventures.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Plexus Ventures, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Plexus Ventures, LLC / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer
Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan
Health Tech Company Hologram Sciences Launches Personalized Health & Nutrition Innovation with 0 Million Backing
DSM Acquires Flavor & Fragrance Bio-based Intermediates Business from Amyris
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow, Inc.





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)